Navigation Links
RANBAXY - enters anti-AIDS segment

The anti-AIDS drug market is currently dominated by the Mumbai based Cipla. Presently, Ranbaxy laboratories, the country's largest pharmaceutical company, is planning to enter the anti-AIDS drugs segment. According to Ranbaxy's regional director for India and west Asia, S D Kaul, the company is in a position to launch Lamivudine, Nevirapine, Aabacavir and Indinavir products in the Indian market shortly.//

Ranbaxy's subsidiary, the Hyderabad-based Vorin Laboratories which is a bulk drug manufacturer, will be formulating the drugs which will be converted to the final drug at Ranbaxy's unit at Dewas in Madhya pradesh. The company has plans for in keeping the vast opportunities for the segment offers. The anti-AIDS drug segment also witnessed the entry of many more pharmaceutical companies including GlaxoSmithKline Pharmaceuticals, Aurobindo Pharmaceuticals and Zydus Cadilla.

Recently, the US based Dade Behring diagnostic company renewed its contract with Ranbaxy, putting an end to the guesswork that the US company would convert the distribution arrangement into a financial bind. Ranbaxy has ruled out the possibility of forming a joint venture with Dade Behring for the diagnostic business, which is a part of Ranbaxy. The company's main motive is to develop this anti-viral drug rather than grab the market share.
'"/>




Page: 1

Related medicine news :

1. Medicis Pharmaceutical company enters pediatric market
2. ZYDUS enters female health care segment
3. Risk of allergy more to children staying in day care centers
4. Walk-In Health Centers Launched By The NHS For Commuters
5. Primary Care centers to provide out patient treatment
6. Free HIV Tests Brings Crowd to the Testing Centers
7. NACO to Introduce 400 Additional AIDS/HIV Screening Centers
8. NACO Inaugurates 37 Additional HIV Treatment Centers
9. Radiotherapy Centers in Scotland Undergo Inspection
10. Are call centers turning a deaf ear to potential acoustic shocks?
11. ‘For-profit Dialysis Centers’ in the Spotlight Over Anti-anemia Drug Overdoe
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... ... March 24, 2017 , ... Vighter established its NAEMT Authorized ... providing Prehospital Trauma Life Support (PHTLS) course scholarships to four medics assigned to ... developed in cooperation with the American College of Surgeons to promote critical thinking ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... world countries to hospitals in the United States, it’s a threat that is ... current obstacles facing infection prevention and offers strategies for the healthcare community to ...
(Date:3/24/2017)... Farifax, VA (PRWEB) , ... March 24, 2017 , ... ... its 2017 Quest Awards . The annual awards, now in their 12th year, ... marketing peers selects the winners. , In 2016, the awards were retooled to recognize ...
(Date:3/24/2017)... ... , ... Texas Physical Therapy Specialists (TexPTS) is pleased to announce the ... clinic is the group’s 7th location in San Antonio and 23rd in Texas. ... care from the clinic, which opened March 22, 2017. , The team ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... related services to families and business owners across eastern Michigan, is connecting with ... families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... LONDON , March 23, 2017 ... comprehensive research report created through extensive primary research ... research, the report aims to present the analysis ... basis of Procedure (Replacement and Repair); Replacement Procedure ... (TAVR)), Repair By Technique (Surgical Devices, Balloon Valvuloplasty, ...
(Date:3/23/2017)... 23, 2017  The U.S. Food and Drug Administration ... treatment of adults and pediatric patients 12 years and ... who have not received prior chemotherapy. This is the ... form of skin cancer. "While skin cancer ... a rare form called Merkel cell cancer have not ...
(Date:3/23/2017)... SAN DIEGO and VANCOUVER, British ... Inc. (NASDAQ: SPHS ) (the "Company" or ... for the treatment of urological diseases, today announced that ... which evaluated the drug as a focal treatment for ... on March 26, 2017 at the 32 nd ...
Breaking Medicine Technology: